NASDAQ · DMRA
Damora Therapeutics, Inc.
$22.01+$0.40 (+1.85%)
Damora Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 42.58% below the high.
Loading market information…
NASDAQ · PHIO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Phio Pharmaceuticals Corp.’s quoted price sits in the lower half of its reported 52-week range, 79.41% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Phio Pharmaceuticals Corp.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.36. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Phio Pharmaceuticals Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.85+30.89% vs estimate |
| $70.00K |
| Q3 2024 | Nov 14, 2024 | -$1.54+62.8% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$22.01+$0.40 (+1.85%)
Damora Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 42.58% below the high.
$1.01+$0.01 (+1.0%)
Marker Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.94% below the high.
$0.93-$0.02 (-2.26%)
BioCardia, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.56% below the high.
$0.98-$0.04 (-3.91%)
IN8bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.1% below the high.
$1.76-$0.60 (-25.42%)
Kiora Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.52% below the high.
$0.49-$0.04 (-8.22%)
Aprea Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.87% below the high.
$1.07$0.00 (0.0%)
Acurx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.81% below the high.
$1.36+$0.06 (+4.62%)
Aptevo Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.22% below the high.
